Blue Corporate Finance exclusively advised the shareholders of the Switzerland-based Alhenia AG on a cross-border sale of all shares to Orchid Orthopedic Solutions, the US-based world-leading provider of contract design and manufacturing solutions for the orthopedic and medical device markets. Blue Corporate Finance managed the transaction process and advised the vendors within all phases of the negotiations. With the acquisition of Alhenia’s coating and machining capabilities Orchid further strengthens its market position in the orthopedic market in Europe.
Alhenia AG, based in Baden-Daettwil, Switzerland, is a world technology and quality leader in medical coatings and one of the leading medical coating companies in Europe. Alhenia’s coating portfolio includes: coatings on peek and polyethylene, ceramic coatings, cold spray coatings, titanium on metal and ceramic substrates and antibacterial coatings. Alhenia has also many years of experience machining implants and instruments along with a wide variety of finishing capabilities to complete the entire value stream of orthopedic components. Alhenia employs approximately 60 people.
Orchid is a worldwide leader in design and manufacturing for the orthopedic and medical device markets. The company’s leading role is underlined by its ability to compress time to market, provide new technologies and deliver the best total supply chain value. Besides coating technologies, Orchid has extensive experience in design and development, quality and regulatory support, implant manufacturing, advanced machining, plastics technology, instrument manufacturing, and packaging services. With 14 world-class facilities located around the globe, Orchid continues to provide others an opportunity to live a better life through products, services and the way they do business. Orchid is a portfolio company of Altor Equity Partners.